Prokidney reports statistically and clinically significant topline results for the phase 2 regen-007 trial evaluating rilparencel in patients with chronic kidney disease and diabetes

Winston-salem, n.c., july 08, 2025 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today reported statistically significant and clinically meaningful positive topline results from the full group 1 modified intent-to-treat (mitt) population of the phase 2 regen-007 trial evaluating rilparencel in patients with ckd and diabetes. rilparencel is an autologous cellular therapy that has received regenerative medicine advanced therapy (rmat) designation from the u.s. food & drug administration (fda) and is currently being evaluated in the ongoing phase 3 regen-006 (proact 1) trial to demonstrate the therapy's potential to preserve kidney function in patients with advanced ckd and type 2 diabetes.
PROK Ratings Summary
PROK Quant Ranking